Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This study has been completed.
Study NCT00001383 Information provided by National Institutes of Health Clinical Center (CC)
First Received on November 3, 1999. Last Updated on March 3, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Cancer
Carcinoma, Renal Cell
Lymphoma
Ovarian Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma
Ovarian Neoplasms
More general conditions related to this trial
Adenocarcinoma
Adnexal Diseases
Breast Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Immune System Diseases
Immunoproliferative Disorders
Kidney Diseases
Kidney Neoplasms
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Skin Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
PSC 833
paclitaxel
Additional drug interventions recognized in this trial
Krestin
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Immunologic Factors
Interferon Inducers
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
